|
Apixaban 2.5 mg twice daily Clinical Trials
1 actively recruiting trial across 1 location
Burlington, Vermont1 trial
DOAC - Dosing Options in AntiCoagulation Prophylaxis
University of Vermont Medical Center
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.